pyrazinamide has been researched along with Recrudescence in 122 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 9.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 9.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2." | 8.02 | Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. ( Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD, 2021) |
| "2% of all tuberculosis (TB) isolates from Canadian-born patients are resistant to pyrazinamide (PZA) alone." | 7.78 | Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. ( Brassard, P; Menzies, D; Yee, DP, 2012) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 7.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 5.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment." | 5.35 | Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 5.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2." | 4.02 | Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. ( Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD, 2021) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "2% of all tuberculosis (TB) isolates from Canadian-born patients are resistant to pyrazinamide (PZA) alone." | 3.78 | Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. ( Brassard, P; Menzies, D; Yee, DP, 2012) |
| "To study the efficacy and safety of Category III DOTS treatment (intermittent thrice-weekly rifampicin [RMP], isoniazid [INH] and pyrazinamide for 2 months, followed by RMP and INH for 4 months) under India's Revised National Tuberculosis Control Programme in patients with uncomplicated small unilateral pleural effusion (<1500 ml)." | 3.78 | Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion. ( Chauhan, LS; Jain, NK; Mohan, A; Sharma, SK; Solanki, R, 2012) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 3.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "The incidence of tuberculosis in Romania has decreased considerably over the past years, particularly since 1972 when the combined rifampicin-ethambutol-pyrazinamide therapy was introduced." | 3.66 | [Tuberculosis in Romania (author's transl)]. ( Anastasatu, C; Plopeanu, D, 1979) |
| "The patients with drug susceptible pulmonary tuberculosis treated with 2HRZE/4H2R2 under the supervision by the pharmacists or the patients treated with 2HRZE/4HR by self-administration were followed-up for two years after completion of chemotherapy." | 2.73 | [Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy]. ( Hoshino, H; Mitarai, S; Ogata, H; Ohmori, M; Okumura, M; Uchimura, K; Wada, M; Yoshiyama, T, 2008) |
| "The currently recommended treatment for lymph node tuberculosis is 6 months of rifampicin and isoniazid plus pyrazinamide for the first 2 months, given either daily or thrice weekly." | 2.71 | Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. ( Ananthalakshmi, V; Chandrasekar, K; Jawahar, MS; Kamaludeen, MN; Paramasivan, CN; Prabhakar, R; Rajaram, K; Sivasubramanian, S; Thirithuvathas, AJ, 2005) |
| "The triple combination studied could replace the separate drugs in the initial treatment phase in countries where the bioavailability of the drugs used has been proven." | 2.68 | [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]. ( Boulahbal, F; Chaulet, P, 1995) |
| "7%]); had similar rates of adverse drug reactions (7." | 2.67 | USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. ( Combs, DL; Geiter, LJ; O'Brien, RJ, 1990) |
| "Relapses have occurred in two of 119 SHRZ6 patients, four of 127 EHRZ6 patients and two of 127 EHR9 patients." | 2.65 | A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. ( , 1984) |
| "Relapse has occurred in 1 of 125 SHRZ6 patients, 3 of 132 EHRZ6, and 2 of 136 EHR9 patients." | 2.65 | A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association. ( , 1982) |
| "All 33 relapses were with strains sensitive to isoniazid and streptomycin, and 76 per cent of them occurred in the first 3 months after the end of chemotherapy." | 2.64 | Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. ( , 1975) |
| "In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M." | 1.48 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. ( Alameda-Martin, L; Coates, A; Davies, G; Harrison, T; Hu, Y; Liu, Y; Ortega-Muro, F; Pertinez, H, 2018) |
| "Sixty-eight eyes (34." | 1.48 | Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis. ( Leong, BCS; Lightman, S; McCluskey, PJ; Tomkins-Netzer, O; Zhang, X, 2018) |
| "Seventeen (4." | 1.43 | Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. ( Cho, YJ; Kim, SJ; Lee, CT; Lee, JH; Lee, JY; Lee, YJ; Park, JS; Song, J; Yoon, HI, 2016) |
| "Pyrazinamide was omitted in 15 cases while rifampicin only in one patient." | 1.38 | Management of and risk factors related to hepatotoxicity during tuberculosis treatment. ( Ağca, S; Arda, H; Babalık, A; Bakırcı, N; Calışır, HC; Cetintaş, G; Kızıltaş, S; Oruç, K, 2012) |
| " In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations." | 1.38 | Therapeutic drug monitoring in the treatment of tuberculosis patients. ( Aarnoutse, R; Boeree, M; Ijdema, D; Magis-Escurra, C; van den Boogaard, J, 2012) |
| "The frequency of late recurrences following treatment completion has not been well-studied." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| "Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model." | 1.35 | Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. ( Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K, 2008) |
| "The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment." | 1.35 | Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008) |
| "To determine the frequency of TB recurrence among MDR (multidrug-resistant) patients who achieved treatment 'success' on standard short-course chemotherapy." | 1.31 | Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. ( Danilova, ID; Espinal, M; Grzemska, M; Migliori, GB; Punga, VV; Raviglione, MC, 2002) |
| "The re-treatment pulmonary tuberculosis with positive spits represent 13." | 1.30 | [The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako]. ( Kayantao, D; Keïta, B; Sangaré, S, 1997) |
| "Although relapse was more frequent in patients with positive smears than those with negative smears (9." | 1.30 | Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? ( Bechan, S; Connolly, C; Short, GM; Standing, E; Wilkinson, D, 1998) |
| "Pyrazinamide, which was readministered last (at the full dose in one case and at progressive doses in the two others), induced a recurrence in two of them." | 1.30 | [Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide]. ( Autret, E; Carré, P; Jonville-Bera, AP; Lemarié, E; Radal, M; Van-Egroo, C, 1998) |
| "Pyrazinamide, which was re-administered last, induced a recurrence." | 1.30 | -Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-. ( Autret, E; Jonville-Béra, AP; Martel, C; Mazaud, S; Olivier, C; Radal, M, 1998) |
| "Three patients presenting with tuberculous lymphadenitis during pregnancy are described." | 1.28 | Reactivation of tuberculous lymphadenitis during pregnancy. ( Khoo, SH; Warner, TT; Wilkins, EG, 1992) |
| "No relapse was noted among patients with extrapulmonary tuberculosis." | 1.28 | [Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load]. ( Morland, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (33.61) | 18.7374 |
| 1990's | 33 (27.05) | 18.2507 |
| 2000's | 20 (16.39) | 29.6817 |
| 2010's | 26 (21.31) | 24.3611 |
| 2020's | 2 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| Ekqvist, D | 1 |
| Bornefall, A | 1 |
| Augustinsson, D | 1 |
| Sönnerbrandt, M | 1 |
| Nordvall, MJ | 1 |
| Fredrikson, M | 1 |
| Carlsson, B | 1 |
| Sandstedt, M | 1 |
| Simonsson, USH | 2 |
| Alffenaar, JC | 1 |
| Paues, J | 1 |
| Niward, K | 1 |
| Pieterman, ED | 1 |
| Keutzer, L | 1 |
| van der Meijden, A | 1 |
| van den Berg, S | 1 |
| Wang, H | 1 |
| Zimmerman, MD | 1 |
| Bax, HI | 1 |
| de Steenwinkel, JEM | 1 |
| Dutta, NK | 2 |
| Pinn, ML | 2 |
| Karakousis, PC | 2 |
| Liu, Y | 2 |
| Pertinez, H | 2 |
| Ortega-Muro, F | 2 |
| Alameda-Martin, L | 2 |
| Harrison, T | 1 |
| Davies, G | 2 |
| Coates, A | 2 |
| Hu, Y | 2 |
| Tomkins-Netzer, O | 1 |
| Leong, BCS | 1 |
| Zhang, X | 1 |
| Lightman, S | 1 |
| McCluskey, PJ | 1 |
| Stagg, HR | 1 |
| Bothamley, GH | 1 |
| Davidson, JA | 1 |
| Kunst, H | 1 |
| Lalor, MK | 1 |
| Lipman, MC | 1 |
| Loutet, MG | 1 |
| Lozewicz, S | 1 |
| Mohiyuddin, T | 1 |
| Abbara, A | 1 |
| Alexander, E | 1 |
| Booth, H | 1 |
| Creer, DD | 1 |
| Harris, RJ | 1 |
| Kon, OM | 1 |
| Loebinger, MR | 1 |
| McHugh, TD | 1 |
| Milburn, HJ | 1 |
| Palchaudhuri, P | 1 |
| Phillips, PPJ | 1 |
| Schmok, E | 1 |
| Taylor, L | 1 |
| Abubakar, I | 1 |
| Alsultan, A | 1 |
| Gniadek, TJ | 1 |
| Belchis, DA | 1 |
| Mdluli, KE | 1 |
| Nuermberger, EL | 2 |
| Peloquin, CA | 1 |
| Wallis, RS | 1 |
| Wang, C | 1 |
| Meyer, D | 1 |
| Thomas, N | 1 |
| Cordero-Coma, M | 1 |
| Garzo, I | 1 |
| Salazar, R | 1 |
| Franco, M | 1 |
| Calleja, S | 1 |
| Ruiz de Morales, JM | 1 |
| Xia, Y | 1 |
| Goel, S | 1 |
| Harries, AD | 1 |
| Zhang, Z | 1 |
| Gao, T | 1 |
| Wang, L | 1 |
| Cheng, S | 1 |
| Lin, Y | 1 |
| Du, X | 1 |
| Nunn, AJ | 1 |
| Cook, SV | 1 |
| Burgos, M | 1 |
| Rigouts, L | 1 |
| Yorke-Edwards, V | 1 |
| Anyo, G | 1 |
| Kim, SJ | 2 |
| Enarson, DA | 1 |
| Jindani, A | 1 |
| Lienhardt, C | 1 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 1 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Okwera, A | 1 |
| Jones-López, EC | 1 |
| Park, JS | 1 |
| Lee, JY | 1 |
| Lee, YJ | 1 |
| Cho, YJ | 1 |
| Yoon, HI | 1 |
| Lee, CT | 1 |
| Song, J | 1 |
| Lee, JH | 1 |
| Dobler, CC | 1 |
| Chidiac, R | 1 |
| Williamson, JP | 1 |
| Jelfs, PJ | 1 |
| Holland, DP | 1 |
| Hamilton, CD | 1 |
| Stout, JE | 1 |
| Schipani, A | 1 |
| Jullien, S | 1 |
| Jain, S | 1 |
| Ryan, H | 1 |
| Ahuja, V | 1 |
| Wada, M | 2 |
| Okumura, M | 1 |
| Hoshino, H | 1 |
| Mitarai, S | 1 |
| Ohmori, M | 1 |
| Uchimura, K | 1 |
| Yoshiyama, T | 1 |
| Ogata, H | 1 |
| Tasneen, R | 1 |
| Tyagi, S | 1 |
| Williams, K | 1 |
| Grosset, J | 1 |
| Nuermberger, E | 1 |
| Rosenthal, IM | 1 |
| Zhang, M | 1 |
| Almeida, D | 1 |
| Grosset, JH | 1 |
| Morrone, N | 1 |
| Morrone Junior, N | 1 |
| Braz, AG | 1 |
| Maia, JA | 1 |
| El Aïdli, S | 1 |
| Kastalli, S | 1 |
| Zaïem, A | 1 |
| Lakhoua, G | 1 |
| Rejeibi, I | 1 |
| Loueslati, MH | 1 |
| Daghfous, R | 1 |
| Belkahia, C | 1 |
| Oxlade, O | 1 |
| Schwartzman, K | 1 |
| Pai, M | 1 |
| Heymann, J | 1 |
| Benedetti, A | 1 |
| Royce, S | 1 |
| Menzies, D | 2 |
| Ishimaru, D | 1 |
| Ogawa, H | 1 |
| Ito, Y | 1 |
| Shimizu, K | 1 |
| Mohapatra, PR | 1 |
| Hari, DT | 1 |
| Mulliez, P | 1 |
| Mbassi Fouda, FL | 1 |
| Roy Saint-Georges, F | 1 |
| Pascopella, L | 1 |
| Deriemer, K | 1 |
| Watt, JP | 1 |
| Flood, JM | 1 |
| Losada, I | 1 |
| Cifuentes, C | 1 |
| Martín, C | 1 |
| García, M | 1 |
| Magis-Escurra, C | 1 |
| van den Boogaard, J | 1 |
| Ijdema, D | 1 |
| Boeree, M | 1 |
| Aarnoutse, R | 1 |
| Yee, DP | 1 |
| Brassard, P | 1 |
| Babalık, A | 1 |
| Arda, H | 1 |
| Bakırcı, N | 1 |
| Ağca, S | 1 |
| Oruç, K | 1 |
| Kızıltaş, S | 1 |
| Cetintaş, G | 1 |
| Calışır, HC | 1 |
| Ruiz-Moreno, JL | 1 |
| Peña-Santos, G | 1 |
| Sharma, SK | 1 |
| Solanki, R | 1 |
| Mohan, A | 1 |
| Jain, NK | 1 |
| Chauhan, LS | 1 |
| Migliori, GB | 1 |
| Espinal, M | 1 |
| Danilova, ID | 1 |
| Punga, VV | 1 |
| Grzemska, M | 1 |
| Raviglione, MC | 1 |
| Chakaya, JM | 1 |
| Kibuga, D | 1 |
| Ng'ang'a, L | 1 |
| Githui, WA | 1 |
| Mansoer, JR | 1 |
| Gakiria, G | 1 |
| Kwamanga, D | 1 |
| Maende, J | 1 |
| Han, JP | 1 |
| Sun, SL | 1 |
| Li, RZ | 1 |
| Zhang, FS | 1 |
| Wang, SC | 1 |
| Cheng, J | 1 |
| Deng, YF | 1 |
| Wang, Y | 1 |
| Yu, CB | 1 |
| Xu, WG | 1 |
| Gao, Z | 1 |
| Fan, BD | 1 |
| PHILLIPS, S | 1 |
| Krasnov, VA | 2 |
| Ursov, IG | 1 |
| Jawahar, MS | 2 |
| Rajaram, K | 1 |
| Sivasubramanian, S | 2 |
| Paramasivan, CN | 2 |
| Chandrasekar, K | 1 |
| Kamaludeen, MN | 1 |
| Thirithuvathas, AJ | 1 |
| Ananthalakshmi, V | 1 |
| Prabhakar, R | 1 |
| Currie, GP | 1 |
| Emmanuel, FX | 1 |
| Ford, D | 1 |
| Devereux, G | 1 |
| Veziris, N | 1 |
| Aubry, A | 1 |
| Truffot-Pernot, C | 1 |
| Kibadi, K | 1 |
| Shennan, DH | 1 |
| Valenzuela, P | 1 |
| Valenzuela, MT | 1 |
| Snider, DE | 2 |
| Graczyk, J | 2 |
| Bek, E | 2 |
| Rogowski, J | 1 |
| Escreet, BC | 1 |
| Cowie, RL | 2 |
| Chaulet, P | 2 |
| Boulahbal, F | 1 |
| de Villiers, CL | 1 |
| Macnab, MF | 1 |
| Chan, SL | 1 |
| Wong, PC | 1 |
| Tam, CM | 1 |
| Tykarski, A | 1 |
| Pupek-Musialik, D | 1 |
| Posadzy-Małaczyńska, A | 1 |
| Potashova, VA | 1 |
| Zyrianova, TV | 1 |
| Naryshkina, SL | 1 |
| Kassim, S | 1 |
| Sassan-Morokro, M | 1 |
| Ackah, A | 1 |
| Abouya, LY | 1 |
| Digbeu, H | 1 |
| Yesso, G | 1 |
| Coulibaly, IM | 1 |
| Coulibaly, D | 1 |
| Whitaker, PJ | 1 |
| Doorly, R | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Kayantao, D | 1 |
| Keïta, B | 1 |
| Sangaré, S | 1 |
| Mitchison, DA | 2 |
| Wilkinson, D | 1 |
| Bechan, S | 1 |
| Connolly, C | 1 |
| Standing, E | 1 |
| Short, GM | 1 |
| el-Sadr, WM | 1 |
| Perlman, DC | 1 |
| Matts, JP | 1 |
| Nelson, ET | 1 |
| Cohn, DL | 2 |
| Salomon, N | 1 |
| Olibrice, M | 1 |
| Medard, F | 1 |
| Chirgwin, KD | 1 |
| Mildvan, D | 1 |
| Jones, BE | 1 |
| Telzak, EE | 1 |
| Klein, O | 1 |
| Heifets, L | 1 |
| Hafner, R | 1 |
| Zeenreich, A | 1 |
| Gochstein, B | 1 |
| Grinshpoon, A | 1 |
| Miron, M | 1 |
| Rosenman, J | 1 |
| Ben-Dov, I | 1 |
| Radal, M | 2 |
| Jonville-Bera, AP | 2 |
| Van-Egroo, C | 1 |
| Carré, P | 1 |
| Lemarié, E | 1 |
| Autret, E | 2 |
| Teo, SK | 1 |
| Choonhakarn, C | 1 |
| Janma, J | 1 |
| Olivier, C | 1 |
| Mazaud, S | 1 |
| Martel, C | 1 |
| Xiao, C | 1 |
| Fu, Y | 1 |
| Li, Z | 1 |
| Sterling, TR | 1 |
| Alwood, K | 1 |
| Gachuhi, R | 1 |
| Coggin, W | 1 |
| Blazes, D | 1 |
| Bishai, WR | 1 |
| Chaisson, RE | 1 |
| Chu, N | 1 |
| Yan, B | 1 |
| Zhu, L | 1 |
| van Loenhout-Rooyackers, JH | 2 |
| Keyser, A | 1 |
| Laheij, RJ | 1 |
| Verbeek, AL | 2 |
| van der Meer, JW | 1 |
| Al-Dossary, FS | 1 |
| Ong, LT | 1 |
| Correa, AG | 1 |
| Starke, JR | 1 |
| Jutte, PC | 1 |
| Krüüner, A | 1 |
| Pehme, L | 1 |
| Ghebremichael, S | 1 |
| Koivula, T | 1 |
| Hoffner, SE | 1 |
| Mikelsaar, M | 1 |
| Fox, W | 2 |
| Mir, MA | 1 |
| Morgan, EJ | 1 |
| Anastasatu, C | 1 |
| Plopeanu, D | 1 |
| Frank, M | 1 |
| Many, M | 1 |
| Sperling, O | 1 |
| Heffernan, JF | 1 |
| Warner, TT | 1 |
| Khoo, SH | 1 |
| Wilkins, EG | 1 |
| Lee, KC | 1 |
| Tami, TA | 1 |
| Lalwani, AK | 1 |
| Schecter, G | 1 |
| Wiesner, B | 1 |
| Cramer, G | 1 |
| Hamel, U | 1 |
| Roth, G | 1 |
| Catlin, BJ | 1 |
| Peterson, KL | 1 |
| Judson, FN | 1 |
| Sbarbaro, JA | 1 |
| Balasubramanian, R | 1 |
| Vijayan, VK | 1 |
| Ramachandran, R | 1 |
| Selvakumar, N | 1 |
| Somasundaram, PR | 1 |
| Combs, DL | 1 |
| O'Brien, RJ | 1 |
| Geiter, LJ | 1 |
| Morland, L | 1 |
| Brändli, O | 1 |
| Haegi, V | 1 |
| Villiger, B | 1 |
| Bohn, W | 1 |
| Baumann, HR | 1 |
| Zäch, R | 1 |
| Baba, H | 2 |
| Shinkai, A | 2 |
| Izuchi, R | 2 |
| Azuma, Y | 2 |
| Kleeberg, HH | 1 |
| Lin, TP | 1 |
| Suo, J | 1 |
| Lee, CN | 1 |
| Lee, JJ | 1 |
| Yang, SP | 1 |
| Zierski, M | 1 |
| Farer, LS | 1 |
| Nikodemowicz, E | 1 |
| Kamińska, M | 1 |
| Kopeć, H | 1 |
| Maternowska, W | 1 |
| Prus, F | 1 |
| Sembratowicz, L | 1 |
| Berkani, M | 1 |
| Darbyshire, JH | 1 |
| Nunn, A | 1 |
| Pines, A | 1 |
| Bartal, M | 1 |
| Nejjar, A | 1 |
| Laraki, A | 1 |
| Lester, W | 1 |
| Neumann, G | 1 |
| Gomi, J | 1 |
| Aoyagi, T | 1 |
| Greene, ME | 1 |
| Stonehill, RB | 1 |
| Bignall, JR | 1 |
| Lind, A | 1 |
| Rist, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Multicenter Phase II-study: Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment Compared With Standardized Treatment in Patients With Mild to Moderate Pulmonary TB[NCT04694586] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for pyrazinamide and Recrudescence
| Article | Year |
|---|---|
Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.
Topics: Follow-Up Studies; Humans; Meta-Analysis as Topic; Microbiological Techniques; Mycobacterium tubercu | 2013 |
Six-month therapy for abdominal tuberculosis.
Topics: Abdomen; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Humans; Isoniazid; Pyrazin | 2016 |
Surgical treatment of an infant with Bacille Calmette-Guérin osteomyelitis extending across the growth plate.
Topics: Anti-Bacterial Agents; BCG Vaccine; Bone Substitutes; Curettage; Durapatite; Growth Plate; Humans; I | 2011 |
[Trends in tuberculosis treatment duration].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2006 |
Tuberculous meningitis: is a 6-month treatment regimen sufficient?
Topics: Adult; Antitubercular Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; Humans | 2001 |
Chemotherapeutic treatment for spinal tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Administration Schedule; Fema | 2002 |
38 trials available for pyrazinamide and Recrudescence
| Article | Year |
|---|---|
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Topics: Adult; Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; | 2022 |
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.
Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol | 2014 |
Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
Topics: Antitubercular Agents; Decision Support Techniques; Ethambutol; Humans; Isoniazid; Markov Chains; Py | 2016 |
[Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Directly Observed Therapy; Drug Administratio | 2008 |
Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Child; Directly Observed Ther | 2005 |
Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1984 |
A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina | 1984 |
Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Evaluation Studies as Top | 1984 |
A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina | 1982 |
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1981 |
Short-course chemotherapy for pulmonary tuberculosis. A 100-day interrupted regimen.
Topics: Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Drug Administration Schedule; Drug Com | 1981 |
[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Drug Tol | 1995 |
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul | 1995 |
A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Black People; Body Weight; Drug Administration Sched | 1996 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antitubercular Agents; Child; Drug Administration Sch | 1997 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
[Long-term efficacy of full course intermittent short-course chemotherapy on new smear positive tuberculosis patients].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid; | 1997 |
Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Humans; I | 1999 |
[Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; H | 1998 |
Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
Topics: Adolescent; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Directly Ob | 2002 |
Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1978 |
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Clinical Trials as Topic; Drug Thera | 1979 |
Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Microbial; Female; | 1975 |
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hon
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug | 1991 |
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Adolescent; Adult; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; | 1991 |
Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Micro | 1990 |
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
Topics: Adult; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Data Interpretation, | 1990 |
[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Topics: Adult; Antitubercular Agents; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; Male; Middle | 1989 |
Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1988 |
Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Thera | 1987 |
Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Iso | 1987 |
Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1986 |
A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as | 1986 |
Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Humans; Isoniazid; | 1985 |
Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Combi | 1972 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.
Topics: Adolescent; Adult; Africa, Eastern; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Dr | 1974 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Africa; Clinical Trials as Topic; Drug Combinations; Drug E | 1974 |
78 other studies available for pyrazinamide and Recrudescence
| Article | Year |
|---|---|
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2021 |
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy | 2017 |
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Thera | 2018 |
Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; | 2018 |
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Duration of Therapy; Etha | 2019 |
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinic | 2013 |
[Treatment of presumed tuberculous uveitis affecting the posterior segment: diagnostic confirmation and long term outcomes].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Humans; Immunocompromised H | 2013 |
Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; China; Cohort Studies; Cost of Il | 2014 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Repeat exposure to active tuberculosis and risk of re-infection.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Emergency Service, Hospital; E | 2016 |
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Female; Isoniazid; Mice; | 2016 |
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; | 2008 |
Gynecomastia: a rare adverse effect of isoniazid.
Topics: Adolescent; Antitubercular Agents; Diagnosis, Differential; Gynecomastia; Humans; Isoniazid; Male; P | 2008 |
Recurrent dysosmia induced by pyrazinamide.
Topics: Antitubercular Agents; Female; Humans; Middle Aged; Olfaction Disorders; Pyrazinamide; Recurrence | 2009 |
[Relapse rate of tuberculosis treated with standard regimen of chemotherapy].
Topics: Adolescent; Aged; Aged, 80 and over; Child; Diabetes Complications; Drug Administration Schedule; Fe | 2009 |
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; HIV Infecti | 2010 |
Predicting outcomes and drug resistance with new standardised treatment.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; Humans; Iso | 2011 |
[Cutaneous reaction after pyrazinamide initiation].
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Eruptions; Drug Therapy, Combination; Dysgeusi | 2011 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
[Sudden decrease in visual acuity and pulmonary infiltrates].
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Laser Coagulation; Ma | 2012 |
Therapeutic drug monitoring in the treatment of tuberculosis patients.
Topics: Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chromatography, High Pr | 2012 |
Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Female; | 2012 |
Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Topics: Adult; Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Drug | 2012 |
[Bilateral tuberculous mastitis nulliparous patient, initially treated as idiopathic granulomatous mastitis].
Topics: Adult; Antitubercular Agents; Diagnostic Errors; Drug Therapy, Combination; Ethambutol; Female; Gran | 2012 |
Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; D | 2012 |
Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Combin | 2002 |
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 2002 |
[The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination; | 2003 |
[Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy].
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male | 2003 |
RELAPSE IN TREATED CASES OF PULMONARY TUBERCULOSIS. I. THREE-YEAR FOLLOW-UP OF 312 PATIENTS DISCHARGED FROM THE HOSPITAL WITH MEDICAL APPROVAL, 1947-1954.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Communicable Disease Control; Foll | 1964 |
[Bactericidal therapy in patients with tuberculosis].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Chlortetracycline; Drug R | 2004 |
Reactivation of tuberculosis after apparently adequate chemoprophylaxis.
Topics: Adolescent; Antitubercular Agents; Chemoprevention; Contact Tracing; Disease Transmission, Infectiou | 2005 |
[Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up].
Topics: Anti-Bacterial Agents; Buruli Ulcer; Child; Chloramines; Combined Modality Therapy; Drug Combination | 2008 |
[Short-course chemotherapy for tuberculosis in Chile. Operational considerations].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; P | 1984 |
Relapse rates in tuberculosis patients.
Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; | 1995 |
Silicotuberculosis: long-term outcome after short-course chemotherapy.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Male; | 1995 |
4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
[Evaluation of uric acid transport in nephrons of patients with calcium nephrolithiasis and hyperuricosuria].
Topics: Absorption; Adult; Benzbromarone; Calcium; Female; Humans; Kidney Calculi; Male; Middle Aged; Nephro | 1993 |
[Clinical aspects and outcome of recurrent pulmonary tuberculosis].
Topics: Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Recurrence; R | 1993 |
[The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako].
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Comb | 1997 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
Topics: Adult; Ambulatory Care; Antibiotics, Antitubercular; Antitubercular Agents; Cohort Studies; Confiden | 1998 |
[Recurrent tuberculosis in a psychiatric hospital, recurrent outbreaks during 1987-1996].
Topics: Antitubercular Agents; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hospitals, P | 1998 |
[Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide].
Topics: Aged; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethambutol; Exanthema; Female | 1998 |
Pyrazinamide-induced lichenoid photodermatitis.
Topics: Antitubercular Agents; Dermatitis, Phototoxic; Dose-Response Relationship, Drug; Drug Eruptions; Dru | 1999 |
-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethamb | 1998 |
[Efficacy of unfixed continuation phase short-course chemotherapy].
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follo | 1997 |
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1999 |
[The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabe | 2000 |
Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Typing Techniques; DNA Fi | 2002 |
Short-course chemotherapy for pulmonary tuberculosis.
Topics: Africa, Eastern; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Drug Thera | 1975 |
Renal excretion of uric acid and its relation to relapse and remission in acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Allopurinol; Creatinine; Female; Homeostasis; Humans; Kidney; Kidney Tubule | 1977 |
Silicosis and tuberculosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Ethionamide; Humans; Isoniazid; Male; | 1979 |
[Tuberculosis in Romania (author's transl)].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Ethambutol; Female; Humans; Infant; Infant, Newbor | 1979 |
Familial renal hypouricaemia: two additional cases with uric acid lithiasis.
Topics: Adult; Calcium; Humans; Jews; Kidney Calculi; Kidney Diseases; Male; Pedigree; Probenecid; Pyrazinam | 1979 |
Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months.
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Microbial; Hong K | 1977 |
Proceedings: Latest results of East African/British Medical Research Council short course chemotherapy studies.
Topics: Drug Evaluation; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Streptomycin; Tuberculosis | 1975 |
Reactivation of tuberculous lymphadenitis during pregnancy.
Topics: Adult; Female; Humans; Isoniazid; Mycobacterium tuberculosis; Pregnancy; Pregnancy Complications, In | 1992 |
Contemporary management of cervical tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Biopsy, Needle; Ethambutol; Female; Humans; Isoniazid; Male; | 1992 |
[Standardized controlled antitubercular therapy and results in 755 patients].
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid | 1991 |
A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspartate Aminotransferases; Cost-Benefit Analysis; | 1990 |
[Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male | 1990 |
[Long-term results of short-course chemotherapy in pulmonary tuberculosis (final report). The third study: comparative study of two regimens, 6RHZ and -6RHS (treatment was continued for 6 months after negative conversion of sputum by culture)].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male; Middle A | 1988 |
[Long-term results of short-course chemotherapy of pulmonary tuberculosis (second study--A). Results up to 6 years after the end of treatment with 4-6 month chemotherapy of pulmonary tuberculosis].
Topics: Adult; Aged; Antitubercular Agents; Follow-Up Studies; Humans; Male; Pyrazinamide; Recurrence; Time | 1987 |
[Studies of short-term chemotherapy of tuberculosis. III. Early and late results of 6 months' treatment of tuberculosis. Analysis of failures and recurrences during 1-5 years' observation].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Ma | 1986 |
[Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Topics: Adult; Algeria; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Eth | 1986 |
Results after retreatment of advanced pulmonary tuberculosis with rifampin and other drugs.
Topics: Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; | 1971 |
Short-course treatment in pulmonary tuberculosis.
Topics: Adolescent; Adult; Africa, Eastern; Antitubercular Agents; Humans; Isoniazid; Mycobacterium tubercul | 1973 |
[Pulmonary tuberculosis resistant to streptomycin and isoniazid and treated wtih a combination of ethionamide, pyrazinamide, and cycloserine (200 cases)].
Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Child; Cycloserine; Drug Resistance, Mic | 1973 |
Treatment of drug-resistant tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr | 1971 |
[Duration of the after-control of the tuberculous patients following the termination of the treatment].
Topics: Adolescent; Adult; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide | 1972 |
Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
Topics: Adult; Body Weight; Drug Therapy, Combination; Ethambutol; Exanthema; Female; Fever; Follow-Up Studi | 1973 |
Shorter treatment.
Topics: Animals; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Time Factors; Tub | 1972 |
Successive manifestations of tuberculosis in a recalcitrant patient.
Topics: Adult; Aminosalicylic Acids; Communicable Disease Control; Hospitalization; Humans; Isoniazid; Male; | 1973 |
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Cycloserine; Ethionamide; Gastrointestina | 1969 |